Literature DB >> 16318875

Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study.

Kazuo Yamada1, Koichiro Watanabe, Naoyuki Nemoto, Hidechika Fujita, Chikayo Chikaraishi, Keita Yamauchi, Gohei Yagi, Masahiro Asai, Shigenobu Kanba.   

Abstract

Neuroleptic noncompliance is a major reason for relapse in outpatients with schizophrenia. In a 2-year follow-up study, we used the Japanese version of the Rating of Medication Influences Scale (ROMI-J) to investigate the reasons for compliance and noncompliance in outpatients with schizophrenia. Ninety outpatients who were confirmed by interview to have had good compliance for more than 3 months completed the initial interview, which included the Clinical Global Impressions Scale (CGI), the Brief Psychiatric Rating Scale (BPRS), the Global Assessment of Functioning Scale (GAF), the UKU Side Effect Rating Scale, and the ROMI-J. All the outpatients were followed up for 2 years. At the initial interview, the most frequent reason for compliance was "relapse prevention," while the most frequent reason for noncompliance was "distressed by side effects." Fifteen outpatients who proved to be noncompliant in the follow-up period had higher baseline BPRS "agitation" scores and ROMI-J "no perceived daily benefit" ratings than compliant patients. Sixty-four outpatients who maintained compliance during the follow-up had higher baseline ROMI-J ratings of "fulfillment of life goals" than their noncompliant counterparts. It is important to understand the attitudes of patients with schizophrenia toward drug therapy in order to predict better compliance and provide psychoeducation designed to forestall relapses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16318875     DOI: 10.1016/j.psychres.2004.07.014

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  11 in total

Review 1.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

2.  Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Rosario de Arce Cordón; Evelin Eding; Joao Marques-Teixeira; Vihra Milanova; Elmars Rancans; Andreas Schreiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-02       Impact factor: 5.270

3.  Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.

Authors:  Wolfgang Gaebel; Andreas Schreiner; Paul Bergmans; Rosario de Arce; Frédéric Rouillon; Joachim Cordes; Lars Eriksson; Enrico Smeraldi
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

Review 4.  Defining and assessing adherence to oral antipsychotics: a review of the literature.

Authors:  Dawn I Velligan; Yui-Wing Francis Lam; David C Glahn; Jennifer A Barrett; Natalie J Maples; Larry Ereshefsky; Alexander L Miller
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

5.  Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand.

Authors:  Sirijit Suttajit; Sutrak Pilakanta
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

6.  Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Enrico Smeraldi; Roberto Cavallaro; Vera Folnegović-Šmalc; Leszek Bidzan; Mehmet Emin Ceylan; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

7.  Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial.

Authors:  Wai Tong Chien; Jolene H C Mui; Eric F C Cheung; Richard Gray
Journal:  Trials       Date:  2015-06-14       Impact factor: 2.279

8.  Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.

Authors:  Suresh Durgam; William M Greenberg; Dayong Li; Kaifeng Lu; Istvan Laszlovszky; Gyorgy Nemeth; Raffaele Migliore; Stephen Volk
Journal:  Psychopharmacology (Berl)       Date:  2016-11-02       Impact factor: 4.530

Review 9.  Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness.

Authors:  Dawn I Velligan; Martha Sajatovic; Ainslie Hatch; Pavel Kramata; John P Docherty
Journal:  Patient Prefer Adherence       Date:  2017-03-03       Impact factor: 2.711

10.  Psychoeducational intervention and prevention of relapse among schizophrenic disorders in the Italian community psychiatric network.

Authors:  Eugenio Aguglia; Elisabetta Pascolo-Fabrici; Francesca Bertossi; Mariano Bassi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.